Fighting
Solid Tumors With
Smart LBP Technology
Delivering hope to patients with
advanced pancreatic cancer and
other aggressive solid tumors.
Saltikva
Saltikva is our lead program in patients with Stage 4, metastatic pancreatic cancer. The Phase 2 results showed that Saltikva was able to dramatically reduce tumor markers, tumor burden, and increase Progression Free Survival and Overall Survival when administered with modified FOLFIRINOX. No serious adverse reactions were caused by Saltikva in the clinical study.
​​
Saltikva will soon enter advanced clinical studies in other aggressive solid tumors.
Testimonials
Safe &
Effective
Over 20 years of research, we have developed a safe vector to deliver the micro-factory for the production of cytokines within the tumor. The production of target drugs intra-tumorally avoids potential complications and toxicity associated with the systemic administration of the same cytokines. Additionally, our LBP vectors cause tumor destruction by two other, recognized modes of action, rendering our technology both safe and effective.
Testimonials
Compassionate Care Patient
“When diagnosed, I did not want very toxic treatments leading to a little more time feeling rotten before dying…. Saltikva is sort of like taking Lipitor, you’ll likely have a good life for longer…”
Regulatory &
Expanded Access
Saltikva is not yet an approved pharmaceutical product. Salspera is currently planning pivotal trials for approval purposes.
​
Saltikva has been awarded Orphan Drug and Fast Track Designations by the US FDA.
​
Salspera will consider all compassionate care requests under Expanded Access, depending on the review of patient criteria and other factors such as drug availability.
​
Leadership
Salspera is managed by an expert team along with a Medical Advisory Panel and Business Advisory Panel.
​
Salspera is opperationally supported by external advisors, consultants and service providers to professionally manage the development of the technology, products and the business.
Eddie Moradian, PhD, Chief Executive Officer
​
Eddie Moradian is a seasoned biotech and life sciences executive having founded / co-founded 10 biotech companies over 30 years He is an experienced investor and operational chief executive of biotech companies involved in the life science research and early-stage drug development sectors.He has extensive experience in bringing advanced R&D to market.Eddie Moradian holds a PhD Degree from the Swiss Federal Institute of Technology in Zurich, Switzerland
Dan Saltzman, MD, PhD Chief Medical Officer
Dan Saltzman is the originator of the technology platform, which is the basis of Salspera today. He is a thought leader who brings leadership and experience in treating patients facing terminal diseases. Dan Saltzman is Chief of Pediatric Surgery at the University of Minnesota. Amongst his many accomplishments was the separation of conjoined twins in 2022. He earned his MD and PhD degrees from the University of Minnesota
News
August 21, 2020
Salspera announces the initiation of its Phase 2 study clinical study in patients with Stage 4, metastatic pancreatic cancer.
April 15, 2022.
Salspera announces receiving Orphan Drug Designation from the FDA for Saltikva in patients with Stage 4 metastatic, pancreatic cancer.
May 20, 2022.
Salspera announces that it has received Fast Track Designation from the FDA for the development of Saltikva in patients with Stage 4 metastatic, pancreatic cancer.
August, 1, 2024.
Salspera announces the closure of its successful Phase 2 study in patients with Stage 4, metastatic pancreatic cancer.
January 25, 2025.
Salspera announces completion of data review showing significant increase in Progression Free Survival (PFS) and Overall Survival (OS) in patients with Stage 4, metastatic pancreatic cancer. Salspera will proceed to planning the next pivotal study for approval.